Patents Assigned to NUVATION BIO INC.
-
Patent number: 11952349Abstract: The disclosure relates to anti-cancer compounds derived from a payload which binds to poly(ADP-ribose) polymerase (PARP) and a nuclear steroid-targeting epitope (B of Formula I), which components are covalently linked via a linker, to products containing the same, as well as to methods of their use and preparation.Type: GrantFiled: November 12, 2020Date of Patent: April 9, 2024Assignee: Nuvation Bio Inc.Inventors: Son Minh Pham, Jayakanth Kankanala, Jeremy Pettigrew, Christopher Paul Miller
-
Patent number: 11834458Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.Type: GrantFiled: March 22, 2022Date of Patent: December 5, 2023Assignee: NUVATION BIO INC.Inventors: David Hung, Jayakanth Kankanala, Christopher Paul Miller, Jeremy David Pettigrew, Son Minh Pham, Ihab S. Darwish
-
Patent number: 11826430Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.Type: GrantFiled: May 13, 2020Date of Patent: November 28, 2023Assignee: NUVATION BIO INC.Inventors: David Hung, Son Minh Pham, Sarvajit Chakravarty, Jiyun Chen, Jayakanth Kankanala, Jeremy D. Pettigrew, Anup Barde, Anjan Kumar Nayak
-
Patent number: 11584756Abstract: Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.Type: GrantFiled: July 1, 2020Date of Patent: February 21, 2023Assignee: NUVATION BIO INC.Inventors: Son Minh Pham, Sarvajit Chakravarty, Jayakanth Kankanala, Jiyun Chen, Chris P. Miller, Jeremy D. Pettigrew, Anjan Kumar Nayak, Anup Barde
-
Publication number: 20220281859Abstract: Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.Type: ApplicationFiled: August 13, 2020Publication date: September 8, 2022Applicant: Nuvation Bio Inc.Inventors: Sarvajit CHAKRAVARTY, Son Minh PHAM, Jayakanth KANKANALA, Jiyun CHEN, Brahmam PUJALA, Bhawana BHATT, Mukesh GANGAR, Amit S. SHETE
-
Patent number: 11332473Abstract: This invention provides for substituted pyrazolo[3,4-d]pyrimidine compounds of the Formula (I): as Wee1 inhibitors. The substituted pyrazolo[3,4-d]pyrimidine compounds may find use as therapeutic agents for the treatment of diseases. The substituted pyrazolo[3,4-d]pyrimidine compounds may also find particular use in oncology.Type: GrantFiled: April 8, 2020Date of Patent: May 17, 2022Assignee: NUVATION BIO INC.Inventors: Sarvajit Chakravarty, Son Minh Pham, Jayakanth Kankanala, Brahmam Pujala, Sanjeev Soni, Puja Jaiswal, Deepak Palve, Varun Kumar
-
Patent number: 11306071Abstract: 5,6-disubstituted 2-aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.Type: GrantFiled: January 17, 2020Date of Patent: April 19, 2022Assignee: Nuvation Bio Inc.Inventors: Son Minh Pham, Jayakanth Kankanala, Pradeep S. Jadhavar, Baban Mohan Mulik, Farha Khan, Sreekanth A. Ramachandran
-
Patent number: 11299493Abstract: Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.Type: GrantFiled: October 9, 2018Date of Patent: April 12, 2022Assignee: Nuvation Bio Inc.Inventors: Sarvajit Chakravarty, Son Minh Pham, Jayakanth Kankanala, Anil Kumar Agarwal, Brahmam Pujala, Sanjeev Soni, Satish K. Arya, Deepak Palve, Ashu Gupta, Varun Kumar
-
Patent number: 11292782Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.Type: GrantFiled: November 27, 2019Date of Patent: April 5, 2022Assignee: Nuvation Bio Inc.Inventors: Sarvajit Chakravarty, Son Minh Pham, Jiyun Chen, Jayakanth Kankanala, Jeremy D. Pettigrew, Anjan Kumar Nayak, Anup Barde, Brahmam Pujala
-
Patent number: 11254670Abstract: 1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.Type: GrantFiled: January 17, 2020Date of Patent: February 22, 2022Assignee: NUVATION BIO INC.Inventors: Son Minh Pham, Jayakanth Kankanala, Pradeep S. Jadhavar, Baban Mohan Mulik, Farha Khan, Sreekanth A. Ramachandran
-
Patent number: 11192900Abstract: Novel bromodomain and extraterminal domain (BET) inhibitors contanining substituted 2-pyridones and therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.Type: GrantFiled: October 30, 2019Date of Patent: December 7, 2021Assignee: Nuvation Bio Inc.Inventors: Son Minh Pham, Sarvajit Chakravarty, Jayakanth Kankanala, Jiyun Chen, Anjan Kumar Nayak, Anup Barde
-
Patent number: 11174252Abstract: Heterocyclic compounds of Formula (J) as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.Type: GrantFiled: February 15, 2019Date of Patent: November 16, 2021Assignee: NUVATION BIO INC.Inventors: Son Minh Pham, Sarvajit Chakravarty, Jayakanth Kankanala, Brahmam Pujala, Amit Shete, Bhawana Bhatt, Anil Kumar Agarwal, Sanjeev Soni, Jiyun Chen
-
Patent number: 11034669Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.Type: GrantFiled: November 27, 2019Date of Patent: June 15, 2021Assignee: Nuvation Bio Inc.Inventors: Sarvajit Chakravarty, Son Minh Pham, Jiyun Chen, Jayakanth Kankanala, Jeremy D. Pettigrew, Anjan Kumar Nayak, Anup Barde, Brahmam Pujala
-
Patent number: 11028058Abstract: Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.Type: GrantFiled: July 18, 2018Date of Patent: June 8, 2021Assignee: NUVATION BIO INC.Inventors: Son Minh Pham, Jiyun Chen, Amantullah Ansari, Pradeep S. Jadhavar, Varshavekumar S. Patil, Farha Khan, Sreekanth A. Ramachandran, Anil Kumar Agarwal, Sarvajit Chakravarty
-
Patent number: 10807994Abstract: Heterocyclic compounds of Formula (I): as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.Type: GrantFiled: October 9, 2018Date of Patent: October 20, 2020Assignee: NUVATION BIO INC.Inventors: Sarvajit Chakravarty, Son Minh Pham, Jayakanth Kankanala, Anil Kumar Agarwal, Brahmam Pujala, Sanjeev Soni, Satish K. Arya, Deepak Palve, Varun Kumar
-
Patent number: 10793561Abstract: 1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.Type: GrantFiled: July 18, 2018Date of Patent: October 6, 2020Assignee: NUVATION BIO INC.Inventors: Son Minh Pham, Jiyun Chen, Amantullah Ansari, Pradeep S. Jadhavar, Varshavekumar S. Patil, Farha Khan, Sreekanth A. Ramachandran, Anil Kumar Agarwal, Sarvajit Chakravarty